Sinocare(SZ:300298)2023-11-29 11:45Group 1: Company Performance - The net profit of PTS for the first three quarters is approximately $6.48 million, while Trividia is still in a loss state despite achieving profitability in the third quarter [2] - As of the end of Q3 2023, the company's cash and cash equivalents amount to approximately $678 million, with a net operating cash flow of $410 million, indicating strong cash flow and sufficient liquidity [4] Group 2: Product Development and Market Strategy - The company's Continuous Glucose Monitoring System (CGMS) received EU MDR certification on September 28, 2023, allowing it to enter the EU market [3] - The CGMS product "Sanofi Aikan" features high accuracy with an i3 MARD value of 8.71% and an h3 MARD value of 7.45%, meeting the high precision monitoring needs of users [3] - The company plans to adopt a sales strategy that considers local policies and market conditions in the EU, leveraging past experiences in BGM sales and developing cross-border e-commerce platforms [3] Group 3: Competitive Advantages - The CGMS product "Sanofi Aikan" offers advantages such as high product quality, user-friendly experience, and good service, making it competitive in the market [4] - The product is designed for easy operation without the need for blood sampling or calibration, providing automatic glucose monitoring every 3 minutes [4] Group 4: Future Financing and Market Demand - The company does not currently plan to adjust the conversion price of its convertible bonds, focusing instead on improving operational efficiency and maintaining investor communication [5] - The company has established both semi-automated and fully automated production lines for CGMS, with plans to adjust production based on market demand [5] Group 5: Industry Outlook - The company believes that non-invasive blood glucose monitoring technology will not significantly impact the CGM industry in the near term, as CGM remains the recommended method for diabetes management [5]